

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1-93. (Canceled)

94. (Currently Amended) An isolated human monoclonal antibody, or antigen binding portion thereof, that binds to human dendritic cells, wherein the antibody comprises a human heavy chain variable region comprising FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 sequences and a human light chain variable region comprising FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 sequences, wherein

(a) the heavy chain CDR3 sequence comprises amino acid residues 99-105 of SEQ ID NO:4 ~~or conservative sequence modifications thereof~~, and the light chain CDR3 sequence comprises amino acid residues 89-97 of SEQ ID NO:2 ~~or conservative sequence modifications thereof~~;

(b) the heavy chain CDR2 sequence comprises amino acid residues 50-66 of SEQ ID NO:4 ~~or conservative sequence modifications thereof~~, and the light chain CDR2 sequence comprises amino acid residues 50-56 of SEQ ID NO:2 ~~or conservative sequence modifications thereof~~; and

(c) the heavy chain CDR1 sequence comprises amino acid residues 31-35 of SEQ ID NO:4 ~~or conservative sequence modifications thereof~~, and the light chain CDR1 sequence comprises amino acid residues 24-34 of SEQ ID NO:2 ~~or conservative sequence modifications thereof~~.

95-98. (Canceled)

99. **(Currently Amended)** An isolated human monoclonal antibody, or antigen binding portion thereof, that binds to human dendritic cells, comprising a human heavy chain variable region comprising the amino acid sequence of SEQ ID NO:4, ~~or conservative sequence modifications thereof,~~ and a human light chain variable region comprising the amino acid sequence of SEQ ID NO:2, ~~or conservative sequence modifications thereof.~~

100. **(Previously Presented)** The antibody or portion of claim 94 or 99, which is internalized following binding to the cells.

101. **(Previously Presented)** The antibody or portion of claim 94 or 99, which specifically binds to human dendritic cells with an affinity of at least  $10^7 \text{ M}^{-1}$ .

102. **(Previously Presented)** The antibody or portion of claim 94 or 99, which activates human dendritic cells.

103. **(Previously Presented)** The antibody or portion of claim 94 or 99, which when linked to an antigen, enhances presentation of the antigen by human dendritic cells following binding to the cells in that the targeted antigen is processed and presented more efficiently compared to the same antigen when not linked to the antibody.

104. **(Previously Presented)** The antibody or portion of claim 94 or 99, which induces cytokine release by human dendritic cells.

105. **(Previously Presented)** The antibody or portion of claim 94 or 99, which binds to the human macrophage mannose receptor comprising the amino acid sequence shown in SEQ ID NO:7.

106. **(Previously Presented)** The antibody or portion, of claim 94 or 99, which dissociates from dendritic cells with a rate constant  $K_{(\text{dis})}$  of  $10^{-3} \text{ S}^{-1}$  or less.

107. **(Previously Presented)** The antibody or portion of claim 94 or 99, which is a single chain antibody or an Fab' fragment.